Pacific Biosciences of California Inc. [NASDAQ: PACB] stock went on a downward path that fall over -2.81% on Monday, amounting to a one-week price increase of more than 2.98%. The company report on October 5, 2020 that Pacific Biosciences Launches the Sequel IIe System to Accelerate Adoption of Highly Accurate HiFi Sequencing.
New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the launch of the Sequel® IIe System, the next instrument evolution based on the company’s Single Molecule, Real-Time (SMRT®) Sequencing technology. With increased computational capacity and on-instrument data processing, the new system can directly produce highly accurate long reads (HiFi reads) more quickly and more cost-effectively than ever, providing scientists with a comprehensive view of genomes and transcriptomes.
Over the last 12 months, PACB stock rose by 155.50%. The one-year Pacific Biosciences of California Inc. stock forecast points to a potential downside of -9.33. The average equity rating for PACB stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.15 billion, with 154.17 million shares outstanding and 151.36 million shares in the current float. Compared to the average trading volume of 3.31M shares, PACB stock reached a trading volume of 7113067 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Pacific Biosciences of California Inc. [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on September 09, 2020, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $5, while Cantor Fitzgerald analysts kept a Overweight rating on PACB stock.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.77, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 26.06. The Price to Book ratio for the last quarter was 48.59, with the Price to Cash per share for the same quarter was set at 0.73. Price to Free Cash Flow for PACB in the course of the last twelve months was 146.23 with Quick ratio for the last quarter at 1.00.
PACB Stock Performance Analysis:
Pacific Biosciences of California Inc. [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.98. With this latest performance, PACB shares gained by 85.31% in over the last four-week period, additionally plugging by 357.94% over the last 6 months – not to mention a rise of 155.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 80.73, with the RSI for the last a single of trading hit 79.60, and the three-weeks RSI is set at 80.45 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 7.64, while it was recorded at 12.75 for the last single week of trading, and 4.76 for the last 200 days.
Insight into Pacific Biosciences of California Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -110.62 and a Gross Margin at +38.04. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at -92.57.
Return on Total Capital for PACB is now -81.97, given the latest momentum, and Return on Invested Capital for the company is -74.59. Return on Equity for this stock declined to -99.58, with Return on Assets sitting at -52.87. When it comes to the capital structure of this company, Pacific Biosciences of California Inc. [PACB] has a Total Debt to Total Equity ratio set at 112.30. Additionally, PACB Total Debt to Total Capital is recorded at 52.90, with Total Debt to Total Assets ending up at 41.67. Long-Term Debt to Equity for the company is recorded at 76.41, with the Long-Term Debt to Total Capital now at 35.99.
Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc. [PACB] managed to generate an average of -$208,252 per employee. Receivables Turnover for the company is 7.62 with a Total Asset Turnover recorded at a value of 0.57.Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
PACB Stock EPS
With the latest financial reports released by the company, Pacific Biosciences of California Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -26.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to 30.00%.
Pacific Biosciences of California Inc. [PACB] Insider Position Details
There are presently around $1,463 million, or 80.80% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: BLACKROCK INC. with ownership of 13,343,578, which is approximately 3.964% of the company’s market cap and around 2.10% of the total institutional ownership; BELLEVUE GROUP AG, holding 8,363,741 shares of the stock with an approximate value of $109.73 million in PACB stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $108.0 million in PACB stock with ownership of nearly 96.312% of the company’s market capitalization.
Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 81 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 12,689,065 shares. Additionally, 53 investors decreased positions by around 18,331,577 shares, while 32 investors held positions by with 80,513,184 shares. The mentioned changes placed institutional holdings at 111,533,826 shares, according to the latest SEC report filing. PACB stock had 33 new institutional investments in for a total of 1,490,460 shares, while 15 institutional investors sold positions of 5,279,158 shares during the same period.